Youngjin Pharmaceutical Expands Scope of KL1333 Technology Transfer... Japan Rights Additionally Transferred, Contract Fee and Milestones to Be Received Separately
Youngjin Pharmaceutical announced on the 5th through a regulatory filing that it has additionally transferred rights to Japan and expanded the scope of technology use in relation to its technology transfer contract for new drug candidate KL1333. [Worldwide Rights Excluding Korea Transferred to Phar

Youngjin Pharmaceutical announced on the 5th through a regulatory filing that it has additionally transferred rights to Japan and expanded the scope of technology use in relation to its technology transfer contract for new drug candidate KL1333.
[Worldwide Rights Excluding Korea Transferred to Pharming]
Youngjin Pharmaceutical signed a supplementary agreement with Pharming Technologies B.V. of the Netherlands on the same day and amended its technology transfer contract disclosure filed on May 2, 2017. The supplementary agreement was signed at 12:07 a.m. on the 5th, Korea time.
Accordingly, Japan was added to the existing scope of rights transfer, which covered 'the entire world excluding Korea and Japan.' As a result, worldwide rights excluding Korea have been transferred to Pharming Technologies B.V.
The scope of the technology transfer was also expanded. Previously, the subject was the KL1333 compound for clinical development in the U.S. and Europe for rare disease indications such as mitochondrial disorders, but through this amendment, pharmaceutically acceptable salts, solvates, prodrugs, stereoisomers, tautomers, isotopes, hydrates, polymorphs, esters, hydrochlorides, free bases, and others are now included.
[Contract Fee of $3 Million and Milestone Payments of $54 Million... Separate Consideration for Japan Rights]
The existing contract terms consist of an upfront payment of $3 million and milestone payments totaling $54 million. The upfront payment is to be received in installments at the time of contract signing, one year after signing, and upon completion of Phase 1 clinical trials in Korea. Milestone payments are to be received sequentially upon the successful achievement of targets at each stage of clinical development, regulatory approval, and price determination.
In addition, the company expects to receive a contract fee, milestone payments, and royalties for the transfer of Japan rights. However, the detailed terms of the additional contract were not disclosed due to a confidentiality agreement and are not included in the existing contract amounts. The disclosure exemption period extends until May 19, 2047.
[Contract Term Until May 19, 2047... Extension Effective Upon Patent Registration]
The contract term is recorded from April 28, 2017 to May 19, 2047. The extension of the contract end date from the previous December 31, 2039 to May 19, 2047 is a conditional supplementary agreement matter, and the extension takes effect only upon completion of patent registration in each individual country.
Youngjin Pharmaceutical stated that there is no obligation to return the contract fee and milestone payments received upon achievement of development targets. It also explained that upon commercialization following regulatory approval, it will receive separate sales milestones and royalties based on sales amounts.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.

